CCS is actively monitoring and responding to the recommendations of the Public Health Agency of Canada regarding coronavirus disease (COVID-19).
Select the text below and copy the link.
AAdult T-cell leukemia/lymphomaAggressive NK-cell leukemiaAIDS-related lymphomaAnaplastic large cell lymphomaAngioimmunoblastic T-cell lymphoma
CChronic lymphocytic leukemia/small lymphocytic lymphomaCutaneous T-cell lymphoma
DDiffuse large B-cell lymphoma
EEnteropathy-associated T-cell lymphomaExtranodal NK/T-cell lymphoma - nasal type
HHepatosplenic T-cell lymphoma
IIntravascular large B-cell lymphoma
LLymphoblastic lymphomaLymphoplasmacytic lymphoma
MMALT lymphomaMantle cell lymphoma
NNodal marginal zone lymphoma
PPeripheral T-cell lymphomaPost-transplant lymphoproliferative disorderPrimary CNS lymphomaPrimary effusion lymphomaPrimary mediastinal large B-cell lymphomaProlymphocytic leukemias
SSplenic marginal zone lymphomaSubcutaneous panniculitis-like T-cell lymphoma
TT-cell large granular lymphocytic leukemia
Or write us. We will reply by email or phone if you leave us your details. If we are not able to reach you by phone, we will leave a voicemail message.
Dr Perreault identified new molecules that may help make immunotherapies work for more people.
The 5-year cancer survival rate has increased from 25% in the 1940s to 60% today.